Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BID | P55957 | 1/20 | 0.64 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.64 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.64 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.64 |
| ▸ | MPO | P05164 | 5/20 | 0.62 |
| ▸ | IGF1R | P08069 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.51 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.51 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11064729 | 0.98 | BID (0.67) | BIDBCL2L1MCL1BAK1MPO | |
| SCHEMBL5540327 | 0.98 | BID (0.67) | BIDBCL2L1MCL1BAK1MPO | |
| SCHEMBL5544698 | 0.98 | BID (0.67) | BIDBCL2L1MCL1BAK1MPO | |
| SCHEMBL8707379 | 0.98 | BID (0.67) | BIDBCL2L1MCL1BAK1MPO | |
| SCHEMBL11097453 | 0.98 | BID (0.67) | BIDBCL2L1MCL1BAK1MPO | |
| Chalcane SCHEMBL1238321 | 0.96 | MPO (0.62) | BIDBCL2L1MCL1BAK1MPO | |
| SCHEMBL3800530 | 0.89 | TAAR1 (0.65) | MPOTAAR1SLC6A4MGLLHSPA5 | |
| Chalcane SCHEMBL27946134 | 0.87 | MPO (0.54) | BIDBCL2L1MCL1BAK1MPO | |
| SCHEMBL987688 | 0.86 | MPO (0.60) | BIDBCL2L1MCL1BAK1MPO | |
| SCHEMBL8401990 | 0.86 | MGLL (0.66) | BIDBCL2L1MCL1BAK1MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-100546963-C | Method for synthesizing bisphenol | GEN ELECTRIC (NL) | 2009-10-07 | — | — | CN | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1741979-A | Process for the synthesis of bisphenol | GEN ELECTRIC (US) | 2006-03-01 | — | — | CN | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| US-20050203179-A1 | Especially suitable for inhibiting the development of body odour in men | CIBA SPECIALTY CHEMICALS CORP. | 2005-09-15 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| CN-1044365-C | Alpha, omega-diarylalkane derivatives, their preparation and their use in the treatment and prevention of circulatory diseases and psychosis | SANKYO CO (JP) | 1999-07-28 | — | — | CN | disclosed |
| EP-0844000-A1 | Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis | SANKYO COMPANY LIMITED (JP) | 1998-05-27 | — | — | EP | disclosed |
| CN-1137788-A | Process for making polyphenols from ketones or aldehydes and phenols | DOW CHEMICAL CO (US) | 1996-12-11 | — | — | CN | disclosed |
| US-5556864-A | TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| CN-1102640-A | Alpha, omega-diarylalkane derivatives, their preparation and their use in the treatment and prevention of circulatory and psychiatric disorders | SANKYO CO (JP) | 1995-05-17 | — | — | CN | disclosed |
| EP-0600717-A1 | Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis | SANKYO COMPANY LIMITED (JP) | 1994-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203179-A1 | Especially suitable for inhibiting the development of body odour in men | SRD5A1, SRD5A2, PON1 | BID 4114/4885BCL2L1 4634/4885MCL1 4752/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | BID 4689/4885BCL2L1 2491/4885MCL1 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.